RCS - Oxford Biomedica PLC - OXB to present at JMP Securities <Origin Href="QuoteRef">OXB.L</Origin>

Oxford BioMedicaAnnouncement

16/07/2015 12:15

RNS Number : 9633Q
Oxford Biomedica PLC
23 June 2015
Oxford BioMedica to present at JMP Securities Life Sciences Conference 2015 in New York and to attend ROTH Healthcare Day in London
Oxford, UK - 23 June 2015: Oxford BioMedica plc ("Oxford BioMedica" or "the Group") (LSE: OXB), a leading gene and cell therapy group, announces that Chief Executive Officer John Dawson will present today at the 2015 JMP Securities Life Sciences Conference in New York at 1600-1630 ET (2100-2130 BST).
Tim Watts, Chief Financial Officer of Oxford BioMedica will also be in attendance at the 2nd Annual ROTH Healthcare Day, held in London on the 24th June 2015.

A live-streaming webcast of the JMP conferencepresentation will be available at http://wsw.com/webcast/jmp27/oxb.l. An archived copy of the presentation will also be made available on the Oxford BioMedica website following the event. 
- Ends -
For further information, please contact:
Oxford BioMedica plc:
John Dawson, Chief Executive Officer
Tim Watts, Chief Financial Officer
Tel: +44 (0)1865 783 000
Consilium Strategic Communications
Mary-Jane Elliott/Matthew Neal/Chris Welsh/Laura Thornton
Tel: +44 (0)20 3709 5700
Notes for editors
About Oxford BioMedica
Oxford BioMedica plc (LSE: OXB) is a leading gene and cell therapy Group with an unrivalled portfolio of gene therapy products in development and a platform of exclusive and pioneering technologies with which it designs, develops and manufactures unique gene-based medicines for some of world's largest pharmaceutical companies. Leveraging its proprietary LentiVector IP and gene delivery system technology platform and unique tumour antigen (5T4), Oxford BioMedica is advancing its pipeline of seven gene therapy products addressing diseases for which there are currently no treatments or that
are inadequately treated today, including ocular and central nervous system disorders. OXB Solutions, the Group's industry-leading manufacturing and development business, provides services to collaborators and partners working in gene and cell therapy, including Novartis and Immune Design Corp. In addition, the Group has licenced products and IP to Sanofi, Pfizer, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions and ImaginAb. Further information is available at www.oxfordbiomedica.co.uk and www.oxbsolutions.co.uk.

This information is provided by RNS
The company news service from the London Stock Exchange
  END
NRAPKNDQKBKDCAB